Diabetes and Infections

Textbook of Diabetes: Fourth Edition

Volumn , Issue , 2010, Pages 835-855

  Cockram, Clive S ^a   Lee, Nelson ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

Bidirectionality: the effect of infections on diabetes; Diabetes; Emphysematous cystitis and emphysematous pyelonephritis; Iatrogenic and surgical site infections; Infections of the urinary tract; Intra abdominal infections other than those within the urinary tract; Prevention and general care; Principles of treatment; Respiratory tract infections and tuberculosis; Skin and superficial soft tissue infections; Specificinfections either strongly associated with diabetes or in which the presence of diabetes is important; The immune system and host factors

Indexed keywords

EID: 84875677268     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444324808.ch50     Document Type: Chapter

References (119)

1. Muller L, Gorter KJ, Hak E, Goudzwaard WL, Schellevis FG, Hoepelman AI, et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis 2005; 41: 281-288.
2. Shah BR, Hux JE. Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care 2003; 26: 510-513.
3. Laupland KB, Gregson DB, Zygun DA, Doig CJ, Mortis G, Church DL. Severe bloodstream infections: a population-based assessment. Crit Care Med 2004; 32: 992-997.
4. Bertoni AG, Saydah S, Brancati FL. Diabetes and the risk of infection -related mortality in the United States. Diabetes Care 2001; 24: 1044-1049.
5. Kornum JB, Thomsen RW, Riis A, Lerving HH, Schonheyder HC, Sorensen HT. Type 2 diabetes and pneumonia outcomes: a population-based cohort study. Diabetes Care 2007; 30: 2251-2257.
6. Booth CM, Matukas LM, Tomlinson GA, Rachlis AR, Rose DB, Dwosh HA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the Greater Toronto Area. JAMA 2003; 289: 2861-2863.
7. Geerlings SE, Hoepelman AIM. Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol Medical Microbiol 1999; 26: 259-265.
8. Lederman MM, Schifman GA, Rodman, HM. Pneumococcal immunization in adults. Diabetes 1981; 30: 119-121.
9. Beam T, Crigler ED, Goldman, JR, Schifmann G. Antibody response to polyvalent pneumococcal polysaccharide vaccine in diabetics. JAMA 1980; 244: 2641-2644.
10. Delamaire M, Maugendre D, Moreno M, Le Goff MC, Allannic H, Genetet B. Impaired leucocyte functions in diabetic patients. Diabet Med 1997; 14: 29-34.
11. Llorente L, De La Fuente H, Richaud-Patin Y, Alvarado-De La Barrera C, Diaz-Borjón A, López-Ponce A, et al. Innate immune response mechanisms in non-insulin dependent diabetes mellitus patients assessed by flow cytoenzymology. Immunol Lett 2000; 74: 239-244.
12. Hostetter MK. Handicaps to host defense: effects of hyperglycemia on C3 and Candida albicans. Diabetes 1990; 39: 271-275.
13. Katz S, Klein B, Elian I, Fishman P, Djaldetti M. Phagocytotic activity of monocytes from diabetic patients. Diabetes Care 1983; 6: 479-482.
14. Park S, Rich J, Hanses F, Lee JC. Defects in innate immunity predispose db/db mice to infection by Staphylococcus aureus. Infect Immun 2009; 77: 1008-1014.
15. Zykova SN, Jenssen TG, Berdal M, Olsen R, Myklebust R, Sljelid R. Altered cytokine and nitric oxide secretion in vitro by macrophages from diabetic type II-like db/db mice. Diabetes 2000; 49: 1451-1458.
16. Offenbacher S, Salvi GE. Induction of prostaglandin release from macrophages by bacterial endotoxin. Clin Infect Dis 1999; 28: 505-513.
17. Geerlings SE, Hoepelman AL. Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol Med Microbiol 1999; 26: 259-265.
18. Amano H, Yamamoto H, Senba M, Oishi K, Suzuki S, Fukushima K, et al. Impairment of endotoxin-induced macrophage inflammatory protein 2 gene expression in alveolar macrophages in streptozotocin -induced diabetes in mice. Infect Immun 2000; 68: 2925-2929.
19. Mazade MA, Edwards MS. Impairment of type III group B streptococcus-stimulated superoxide production and opsonophagocytosis by neutrophils in diabetes. Mol Genet Metab 2001; 73: 259-267.
20. Al-Mashat HA, Kandru S, Liu R, Behl Y, Desta T, Graves DT. Diabetes enhances mRNA levels of proapoptotic genes and caspase activity, which contribute to impaired healing. Diabetes 2006; 55: 487-495.
21. Li YM. Glycation ligation binding motif in lactoferrin: implications in diabetic infection. Adv Exp Med Biol 1998; 443: 57-63.
22. Falagas ME, Kompoti M. Obesity and infection. Lancet Infect Dis 2006; 6: 438-446.
23. Ferguson BJ. Mucormycosis of the nose and paranasal sinuses. Otolaryngol Clin North Am 2000; 33: 349-365.
24. Tsay WR, Siu LK, Fung CP, Chang FY. Characteristics of bacteraemia between community-acquired and nosocomial Klebsiella pneumoniae infection: risk factor for mortality and the impact of capsular serotypes as a herald for community-acquired infection. Arch Intern Med 2002; 162: 1021-1027.
25. Yinnon AM, Butnaru A, Raveh D, Jerassy Z, Rudensky B. K lebsiella bacteraemia: community versus nosocomial infection. Q J Med 1996; 89: 933-941.
26. Lee KH, Hui KP, Tan WC, Lim TK. Klebsiella bacteremia: a report of 101 cases from National University Hospital, Singapore. J Hosp Infect 1994; 27: 299-305.
27. Chung DR, Lee SS, Lee HR, Kim HB, Choi HJ, Eom JS, et al. Emerging invasive liver abscess caused by K1 serotype Klebsiella pneumoniae in Korea. J Infect 2007; 54: 578-583.
28. Chanchamroen S, Kewcharoenwong C, Susaengrat W, Ato M, Lertmemongkolchai G. Human polymorphonuclear neutrophil responses to Burkholderia pseudomallei in healthy and diabetic subjects. Infect Immun 2009; 77: 456-463.
29. Van der Werf N, Kroese FGM, Rozing J, Hillebrands JL. Viral infections as potential triggers of type 1 diabetes. Diabetes Metab Res Rev 2007; 23: 169-183.
30. Akatsuka H, Yano EC, Gabazza J, Morser J, Sasaki R, Suzuki T, et al. A case of fulminant type 1 diabetes with coxsackie B4 virus infection diagnosed by elevated serum levels of neutralizing antibody. Diab Res Clin Pract 2009; 84:e50-e52.
31. Wills-Karp M, Santeliz J, Karp CL. The germless theory of allergic disease: revisiting the hygiene hypothesis. Nat Rev Immunol 2001; 1: 69-74.
32. Ling P, Bistrian B, Mendez B, Istfan NW. Effects of systemic infusion of endotoxin, tumour necrosis factor and interleukin-1 on glucose metabolism in the rat: relationship to endogenous glucose metabolism and peripheral tissue glucose uptake. Metabolism 1994; 43: 279-284.
33. Mason AL, Lau JY, Hoang N, Qian K, Alexander GJ, Xu L, et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 29: 328-333.
34. Grimbert S, Valensi P, Lévy-Marchal C, Perret G, Richardet JP, Raffoux C, et al. High prevalence of diabetes mellitus in patients with chronic hepatitis C: a case-control study. Gastroenterol Clin Biol 1996; 20: 544-548.
35. Knobler H, Stagnaro-Green A, Wallenstein S, Schwartz M, Roman SH. Higher incidence of diabetes in liver transplant recipients with hepatitis C. J Clin Gastroenterol 1998; 26: 30-33.
36. Ozyilkan E, Arslan M. Increased prevalence of diabetes mellitus in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1996; 91: 1480-1481.
37. Simo R, Hernandez C, Genesca J, Jardi R, Mesa J. High prevalence of hepatitis C virus infection in diabetic patients. Diabetes Care 1996; 19: 998-1000.
38. Caronia S, Taylor K, Pagliaro L, Carr C, Palazzo U, Petrik J, et al. Further evidence for an association between non-insulin dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 30: 1059-1063.
39. Mehta SH, Brancati FL, Sulkowski MS, Steffanie A, Strathdee MS, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000; 133: 592-599.
40. Knobler H, Schattner A. TNF-a, chronic hepatitis C and diabetes: a novel triad. Q J Med 2005; 98: 1-6.
41. Howard AA, Klein RS, Schoenbaum EE. Association of hepatitis C infection and antiretroviral use with diabetes mellitus in drug users. Clin Infect Dis 2003; 36: 1318-1323.
42. Samaras K. Prevalence and pathogenesis of diabetes mellitus in HIV-1 infection treated with combined antiretroviral therapy. J Acquir Immune Defic Syndr 2009; 50: 499-505.
43. Tebas P. Insulin resistance and diabetes mellitus associated with antiretroviral use in HIV-infected patients: pathogenesis, prevention, and treatment options. J Acquir Immune Defic Syndr 2008; 49 (Suppl 2): S86-S92.
44. Wand H, Calmy A, Carey DL, Samaras K, Carr A, Law MG, et al. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS 2007; 21: 2445-2453.
45. Samaras K, Wand H, Law M, Emery S, Cooper D, Carr A. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia. Diabetes Care 2007; 30: 113-119.
46. Ledergerber B, Furrer H, Rickenbach M, Lehmann R, Elzi L, Hirschel B, et al. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. Clin Infect Dis 2007; 45: 111-119.
47. Wohl DA, McComsey G, Tebas P, Brown TT, Glesby MJ, Reeds D, et al. Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. Clin Infect Dis 2006; 43: 645-653.
48. Lundgren JD, Battegay M, Behrens G, et al.; EACS Executive Committee). European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med 2008; 9: 72-81.
49. Schambelan M, Benson CA, Carr A, Currier JS, Dubé MP, Gerber JG, et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr 2002; 31: 257-275.
50. Papatheodoridis GV, Chrysanthos N, Savvas S, Sevastianos V, Kafiri G, Petraki K, et al. Diabetes mellitus in chronic hepatitis B and C: prevalence and potential association with the extent of liver fibrosis. J Viral Hepat 2006; 13: 303-310.
51. Cheng AY, Kong AP, Wong VW, So WY, Chan HL, Ho CS, et al. Chronic hepatitis B viral infection independently predicts renal outcome in type 2 diabetic patients. Diabetologia 2006; 49: 1777-1784.
52. Chandler JR. Malignant external otitis. Laryngoscope 1968; 78: 1257-1294.
53. Grandis JR, Branstetter IV BF, Yu VL. The changing face of malignant (necrotising) external otitis: clinical, radiological, and anatomic correlations Lancet Infect Dis 2004; 4: 34-39.
54. Lee FYW, Mossad SB, Adal KA. Pulmonary mucormycosis: the last 30 years. Arch Intern Med 1999; 59: 1301-1307.
55. Roden MM, Zaoutis TE, Buchana WL, Knudsen TA, Sarkisova TA, Walsh TJ. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41: 634-653.
56. Ghadiali MT, Deckard NA, Farooq U, Astor F, Robinson P, Casiano RR. Frozen-section biopsy analysis for acute invasive fungal rhinosinusitis. Otolarngology 2007; 136: 714-719.
57. Walmsley RS, David DB, Allan RN, Kirkby GR. Bilateral endogenous Escherichia coli endophthalmitis: a devastating complication in an insulin-dependent diabetic. Postgrad Med J 1996; 72: 361-363.
58. Karacal H, Kymes SM, Apte RS. Retrospective analysis of etiopathogenesis of all cases of endophthalmitis at a large tertiary referral center. Int Ophthalmol 2007; 27: 251-259.
59. Oliver RC, Tervonen T. Periodontitis and tooth loss: comparing diabetics with the general population. J Am Dent Assoc 1993; 124: 71-76.
60. Ljubic S, Balachandran A, Pavlic-Renar I. Pulmonary infections in diabetes mellitus. Diabetol Croat 2005; 4: 115-124.
61. Marrie TJ. Bacteraemic pneumococcal pneumonia: a continuously evolving disease. J Infect 1992; 24: 247-255.
62. Lee N, Chan PK, Hui DC, Rainer TH, Wong E, Choi KW, et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis 2009; 200: 492-500.
63. Lipsky BA, Pecoraro RE, Chen MS, Koepsell TD. Factors affecting staphylococcal colonization among NIDDM outpatients. Diabetes Care 1987; 10: 483-486.
64. Valdez R, Narayan KM, Geiss LS, Engelgau MM. Impact of diabetes mellitus on mortality associated with pneumonia and influenza among non-Hispanic black and white US adults. Am J Public Health 1999; 89: 1715-1721.
65. Cheu KY, Hsueh PR, Liaw YS, Yang PC, Luh K. A 10 year experience with bacteriology of acute thoracic empyema. Chest 2000; 117: 1685-1689.
66. Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Medicine 2008; 5; e152: doi:10.1371/journal.pmed.0050152.
67. Stevenson CR, Forouhi NG, Roglic G, Williams BG, Lauer JA, Dye C, et al. Diabetes and tuberculosis: the impact of the diabetes epidemic on tuberculosis incidence. BMC Public Health 2007; 7: 234.
68. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003; 163: 1009-1021.
69. Wang JY, Lee LN, Hsueh PR. Factors changing the manifestation of pulmonary tuberculosis. Int J Tuberc Lung Dis 2005; 9: 777-783.
70. Alisjahbana B, Sahiratmadja E, Nelwan EJ, Purwa AM, Ahmad Y, Ottenhoff TH, et al. The effect of type 2 diabetes on presentation and treatment response of pulmonary tuberculosis. Clin Infect Dis 2007; 45: 428-435.
71. Nijland HM, Ruslami R, Stalenhoef JE, Nelwan EJ, Alisjahbana B, Nelwan RH, et al. Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. Clin Infect Dis 2006; 43: 848-854.
72. Harding GM, Zhanel GG, Nicolle L, Cheung M. Antimicrobial treatment in diabetic women with asymptomatic bacteriuria. N Engl J Med 2002; 347: 1576-1583.
73. Stapleton A. Urinary tract infections in patients with diabetes. Am J Med 2002; 113: 80S-84S.
74. Geerlings SE, Stolk RP, Camps MJL, Netten PM, Collet JT, Schneeberger PM, et al. Consequences of asymptomatic bacteriuria in women with diabetes mellitus. Arch Intern Med 2001; 161: 1421-1427.
75. Hu KK, Boyko EJ, Scholes D, Normand E, Normand E, Chen CL, Grafton J, et al. Risk factors for urinary tract infections in postmenopausal women. Arch Intern Med 2004; 164: 989-993.
76. Scholes D, Hooton TM, Roberts PL, Gupta K, Stapleton AE, Stamm WE. Risk factors associated with acute pyelonephritis in healthy women. Ann Intern Med 2005; 142: 20-27.
77. Efstathiou SP, Pefanis AV, Tsioulos DL, Zacharos ID, Tsiakou AG, Mitromaras AG, et al. Acute pelonephritis in aults: prediction of mortality and failure of treatment. Arch Intern Med 2003; 163: 1206-1212.
78. Meiland R, Geerlings SE, Hoepelman ALM. Management of bacterial urinary tract infections in adult patients with diabetes mellitus. Drugs 2002; 62: 1859-1868.
79. Geerlings SE, Stolk RP, Camps MJL, Netten PM, Collet TJ, Hoepelman AI; Diabetes Women Asymptomatic Bacteriuria Utrecht Study Group. Risk factors for symptomatic urinary tract infection in women with diabetes. Diabetes Care 2000; 23: 1737-1741.
80. Vasquez JA, Sobel JD. Fungal infections in diabetes. Infect Dis Clin North Am 1995; 9: 97-116.
81. Wright SW, Wrenn KD, Haynes M, Haas DW. Prevalence and risk factors for multidrug resistant uropathogens in ED patients. Am J Emerg Med 2000; 18: 143-146.
82. Edelstein H, Mccabe RE. Perinephric abscess: modern diagnosis and treatment in 47 cases. Medicine (Baltimore) 1988; 67: 118-131.
83. Grupper M, Kravtsov A, Potasman I. Emphysematous cystitis: illustrative case report and review of the literature. Medicine 2007; 86: 47-53.
84. Stamm WE, Hooton TM. Management of urinary tract infections in adults. N Engl J Med 1993; 329: 1328-1334.
85. Moutzouris DA, Michalakis K, Manetas S. Severe emphysematous pyelonephritis in a diabetic patient. Lancet Infect Dis 2006; 6: 614.
86. Huang JJ, Tseng CC. Emphysematous pyelonephritis: clinicoradiological classification, management, prognosis, and pathogenesis. Arch Intern Med 2000; 160: 797-805.
87. Pontin AR, Barnes RD. Current management of emphysematous pyelonephritis. Nat Rev Urol 2009; 6: 272-279.
88. Tellez LG, Rodrigues-Montes JA, de Lis SF, Marten LG. Acute emphysematous cholecystitis: report of twenty cases. Hepatogastroenterol 1999; 46: 2144-2148.
89. Elsayes KM, Menias CO, Sierra L, Dillman JR, Platt JF. Gastrointestinal manifestations of diabetes mellitus: spectrum of imaging findings. J Comput Assist Tomogr 2009; 33: 86-89.
90. Shrestha Y, Trottier S. Images in clinical medicine: emphysematous cholecystitis. N Engl J Med 2007; 357: 1238.
91. Chang FY, Chou MY. Comparison of pyogenic liver abscesses caused by Klebsiella pneumoniae and non-K pneumoniae pathogens. J Formos Med Assoc 1995; 94: 232-237.
92. Chang FY, Chou MY, Fan RL, Shaio MF. A clinical study of Klebsiella liver abscess. J Formos Med Assoc 1988; 88: 1008-1011.
93. Wang JH, Liu YC, Lee SS, Yen MY, Chen YS, Wang JH, et al. Primary liver abscess due to Klebsiella pneumoniae in Taiwan. Clin Infect Dis 1998; 26: 1434-1438.
94. Kim JK, Chung DR, Wie SH, Yoo JH, Park SW. Risk factor analysis of invasive liver abscess caused by the K1 serotype Klebsiella pneumoniae. Eur J Clin Microbiol Infect Dis 2009; 28: 109-111.
95. Tsai FC, Huang YT, Chang LY, Wang JT. Pyogenic liver abscess as endemic disease, Taiwan. Emerg Infect Dis 2008; 14: 1592-1600.
96. Thomsen RW, Jepsen P, Sorensen HT. Diabetes mellitus and pyogenic liver abscess: risk and prognosis. Clin Infect Dis 2007; 44: 1194-1201.
97. Grau I, Vadillo M, Cisnal M, Pallares R. Bacteremic pneumococcal cellulitis compared with bacteremic cellulitis caused by Staphylococcus aureus and Streptococcus pyogenes. Eur J Clin Microbiol Infect Dis. 2003; 22: 337-341.
98. Graham PL 3rd, Lin SX, Larson EL. A US population-based survey of Staphylococcus aureus colonization. Ann Intern Med 2006; 144: 318-325.
99. Fridkin SK, Hageman JC, Morrison M, et al.; for the Active Bacterial Core Surveillance Program of the Emerging Infections Program Network. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005; 352: 1436-1444.
100. Tapper-Jones LM, Aldred MJ, Walker DM, Hayes TM. Candidal infections and populations of Candida albicans in mouths of diabetics. J Clin Pathol 1981; 34: 706-711.
101. Farrer SM, Macleod CM. Staphylococcal infections in a general hospital. Am J Hyg 1960; 72: 38-58.
102. Cluff LE, Reynolds RC, Page DL. Staphylococcal bacteraemia: demographic, clinical and microbiological features of 185 cases. Trans Am Clin Climatol Assoc 1968; 79: 905-915.
103. Farley DE, Katz VL, Dotters D. Toxic shock syndrome associated with vulva necrotizing fasciitis. Obstet Gynaecol 1993; 82: 660-662.
104. Miller LG, Perdreau-Remington F, Rieg G, Mehdi S, Perlroth J, Bayer AS, et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med 2005; 352: 1445-1453.
105. Howard RJ, Bennett NT. Infections caused by halophilic marine Vibrio bacteria. Ann Surg 1993; 217: 525-531.
106. Clayton MD, Fowler JE Jr, SharifiR, Pearl RK. Causes, presentation and survival of 57 patients with necrotizing fasciitis of the male genitalia. Surg Gynaecol Obstet 1990: 49-55.
107. Smith GL, Bunker CB, Dinneen MD. Fournier's gangrene. Br J Urol 1998; 81: 347-355.
108. Cunningham ME, Girardi F, Papadopoulos EC, Cammisa FP. Spinal infections in patients with compromised immune systems. Clin Orthop Relat Res 2006; 444: 73-82.
109. Lew DP, Waldvogel FA. Osteomyelitis. Lancet 2004; 364: 369-379.
110. Brink SJ, Stewart C. Insulin pump treatment in insulin-dependant diabetic children, adolescents and young adults. JAMA 1986; 255: 617-621.
111. Latham R, Lancaster AD, Covington JF, Pirolo JS, Thomas CS. The association of diabetes and glucose control with surgical-site infections among cardiothoracic surgery patients. Infect Control Hosp Epidemiol 2001; 22: 607-612.
112. Golden SH, Peart-Vigilance C, Kao WH, Brancati FL. Perioperative glycemic control and the risk of infectious complications in a cohort of adults with diabetes. Diabetes Care 1999; 22: 1408-1414.
113. Guvener M, Pasaoglu I, Demircin M, Oc M. Perioperative hyperglycemia is a strong correlate of postoperative infection in type II diabetic patients after coronary artery bypass grafting. Endocr J 2002; 49: 531-537.
114. Estrada CA, Young JA, Nifong W, Chitwood WR Jr. Outcomes and perioperative hyperglycemia in patients with or without diabetes mellitus undergoing coronary artery bypass grafting. Ann Thorac Surg 2003; 75: 1392-1399.
115. Marelli D, Laks H, Patel B, Kermani R, Marmureanu A, Patel J, et al. Heart transplantation in patients with diabetes mellitus in the current era. J Heart Lung Transplant 2003; 22: 1091-1097.
116. Thomas MC, Mathew TH, Russ GR, Rao MM, Moran J. Early peri-operative glycaemic control and allograft rejection in patients with diabetes mellitus: a pilot study. Transplantation 2001; 72: 1321-1324.
117. Davenport A. Peritonitis remains the most important complication of peritoneal dialysis: the London, UK, peritonitis audit 2002-2003. Perit Dial Int 2009; 29: 297-302.
118. Colquhoun AJ, Nicholson KG, Botha JL, Raymond NT. Effectiveness of influenza vaccine in reducing hospital admissions in people with diabetes. Epidemiol Infect 1997; 119: 335-341.
119. American Diabetes Association. Clinical practice recommendations 2009. Diabetes Care 2009; 32 (Suppl. 1): S13-S61.